Home > Protocol Summaries: Compounds > dabrafenib Protocol Summaries: dabrafenib GSKStudy ID Phase Title Status 112680 phase 1 A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects with Solid Tumors Completed 113220 phase 2 An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and ClinicalActivity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma Active not recruiting 113468 phase 1 An Open-Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects with BRAF Mutation-Positive Tumor Completed 113479 phase 1 Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered with an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects with BRAF Mutant Solid Tumors Completed 113710 phase 2 A Phase II (BRF113710) single-arm, open-label study of GSK2118436 in BRAF mutant metastatic melanoma Active not recruiting 113773 phase 1 A Two-Part Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects with V600 BRAF Mutation-Positive Tumors: An Open-label, Dose-escalating Safety Lead-in Study Followed by a Single-sequence, Placebo-controlled, Single-blind Study Recruiting 115532 phase 3 COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection Recruiting 115984 phase 1 Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination with Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma Recruiting 116013 phase 1 Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors Recruiting 116056 phase 1 An open-label, dose escalation, phase I study to evaluate the safety, tolerability and pharmacokinetic profile of GSK2118436 in Japanese subjects with BRAF V600 mutation positive solid tumors. Recruiting 116604 n\a PGx6039 PGx Investigation of Pyrexia in Subjects Receiving GSK2118436 Monotherapy Active not recruiting 200146 Evaluation of Patient Tolerability Associated with Vemurafenib Treatment of Advanced or Metastatic Melanoma Not yet recruiting
